<DOC>
	<DOCNO>NCT00002641</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether give chemotherapy surgery effective surgery alone treat soft tissue sarcoma . PURPOSE : Randomized phase III trial compare effectiveness surgery without chemotherapy treat patient soft tissue sarcoma .</brief_summary>
	<brief_title>Surgery With Without Chemotherapy Treating Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare local disease control , overall survival , relapse-free survival patient high-grade soft tissue sarcoma treat adjuvant high-dose doxorubicin ifosfamide plus filgrastim ( G-CSF ) v adjuvant chemotherapy G-CSF definitive surgery . - Compare toxicity morbidity regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord center , site primary tumor ( extremity v trunk , include shoulder , pelvic girdle , head , neck vs central , include intrathoracic , visceral , uterine , retroperitoneal ) , size primary tumor ( le 5 cm v 5 cm great large diameter ) , postoperative radiotherapy ( yes v ) , isolated limb perfusion therapy ( yes v ) . Some patient undergo isolated limb perfusion therapy cytotoxics and/or cytokine . No 8 week biopsy inadequate surgery , patient undergo definitive surgery . Patients complete resection undergo radiotherapy assessment randomization . Patients incomplete marginal resection ( except central lesion ) undergo re-excision , absence macroscopic disease , assessment postoperative radiotherapy follow randomization . - Randomization : Patients randomize 1 2 treatment arm . - Arm I : Patients receive adjuvant chemotherapy filgrastim ( G-CSF ) . Beginning within 6 week surgery , eligible patient undergo radiotherapy outline . - Arm II : Beginning within 4 week surgery , patient receive high-dose doxorubicin IV 20 minute follow ifosfamide IV 24 hour G-CSF subcutaneously daily begin 24 hour completion ifosfamide infusion continue 10 day . Treatment continue every 3 week 5 course . Beginning within 6 week completion chemotherapy , eligible patient undergo radiotherapy outline . - Radiotherapy : Patients incomplete marginal resection undergo radiotherapy 5 day week 6-6.6 week . Patients complete microscopic resection undergo radiotherapy 5 day week 5 week follow boost radiotherapy 5 day week 1 week . Patients follow every 2 month 1 year , every 3 month 2 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 350 patient accrue study within 3.5 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven soft tissue sarcoma amenable definitive surgery 8 week biopsy inadequate surgery Eligible subtypes : Alveolar soft part sarcoma Angiosarcoma Fibrosarcoma Leiomyosarcoma Malignant fibrous histiocytoma Liposarcoma ( round cell pleomorphic ) Miscellaneous sarcoma ( include pelvic mixed mesodermal tumor ) Malignant paraganglioma Neurogenic sarcoma Rhabdomyosarcoma Synovial sarcoma Unclassifiable sarcoma Ineligible subtypes : Chondrosarcoma Dermatofibrosarcoma Embryonal rhabdomyosarcoma Ewing 's sarcoma Kaposi 's sarcoma Liposarcoma ( myxoid well differentiate ) Malignant mesothelioma Neuroblastoma Osteosarcoma Confirmed highgrade tumor ( i.e. , Trojani Grade II III ) No metastases stag chest xray thoracic CT scan No regional lymph node involvement Locally recurrent disease allow Interval 3 month definitive surgery recurrence PATIENT CHARACTERISTICS : Age : 16 69 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm^3 Platelet count great 120,000/mm^3 No bleeding disorder Hepatic : Bilirubin great 1.25 time normal No severe hepatic dysfunction Renal : Creatinine le 1.6 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No clear history angina No document myocardial infarction No exist cardiac failure Other : No serious infection No malignancy except adequately treat carcinoma situ cervix basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy affect area Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>adult alveolar soft-part sarcoma</keyword>
	<keyword>adult epithelioid sarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>localize benign pheochromocytoma</keyword>
	<keyword>regional pheochromocytoma</keyword>
	<keyword>recurrent pheochromocytoma</keyword>
	<keyword>stage II uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine carcinosarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>endometrial stromal sarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>clear cell sarcoma kidney</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
</DOC>